Natco pharma Limited has submitted mandatory disclosures under SEBI regulations for the financial year ended March 31, 2026. The pharmaceutical company filed the required documentation with both BSE and NSE on April 3, 2026, fulfilling its regulatory obligations under the substantial acquisition framework.

Regulatory Filing Details

The disclosure was filed under Regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. Company Secretary and Compliance Officer Ch. Venkat Ramesh submitted the filing on behalf of the company to both stock exchanges.

Promoter Group Confirmation

Sri V.C. Nannapaneni, Promoter of NATCO Pharma, provided a separate confirmation dated April 4, 2026, addressing the encumbrance status of promoter holdings. The confirmation was submitted on behalf of himself, other Promoters, Members of the Promoter Group, and Persons Acting in concert.

Share Encumbrance Status

The promoter group confirmed that shares held in NATCO Pharma Limited were not encumbered or pledged during the financial year ended March 31, 2026. This confirmation covers:

• Direct shareholdings by promoters
• Indirect shareholdings by promoter entities
• Holdings by Members of the Promoter Group
• Shares held by Persons Acting in concert

Corporate Governance Compliance

The filing demonstrates NATCO Pharma's adherence to SEBI's transparency requirements for substantial shareholding disclosures. The company maintains its registered office at 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad, and continues to fulfill its listing obligations on both BSE and NSE.

The disclosure was also shared with the company's Audit Committee as part of internal governance protocols, ensuring comprehensive compliance with regulatory frameworks governing substantial acquisitions and takeovers in the Indian capital markets.

Natco pharma Limited has submitted its quarterly compliance certificate under SEBI Regulation 74(5) for the quarter ended March 31, 2026, demonstrating adherence to regulatory requirements for securities dematerialization and depository management.

Regulatory Filing Details

The pharmaceutical company filed the mandatory certificate with both major stock exchanges on April 8, 2026. Company Secretary and Compliance Officer Ch. Venkat Ramesh submitted the documentation to BSE Limited and National Stock Exchange of India Limited, fulfilling the quarterly reporting obligations.

Compliance Certification

Venture Capital and Corporate Investments Private Limited, serving as the registrar and transfer agent, issued the compliance certificate confirming proper handling of dematerialization processes. The certificate validates that all securities received for dematerialization during the quarter were processed according to regulatory standards.

The registrar certified that securities were mutilated and cancelled after due verification, with depository records updated within the mandatory 15-day timeframe. Both National Securities Depository Limited (NSDL) and Central Depository Services (India) Limited (CDSL) were properly updated as registered owners in the company's records.

Depository Operations

The certificate confirms compliance with key operational requirements:

• Proper verification and cancellation of physical securities
• Timely updating of depository records within 15 days
• Maintenance of accurate ownership records for both NSDL and CDSL
• Furnishing of security details to relevant stock exchanges

Corporate Information

Natco Pharma Limited operates from its registered office at 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad, with CIN L24230TG1981PLC003201. The company maintains its compliance framework through designated officers who ensure adherence to SEBI regulations and stock exchange requirements.

The quarterly filing represents part of the company's ongoing regulatory obligations, ensuring transparency in securities handling and maintaining investor confidence through proper depository management practices.